This segment focuses on the development and commercialization of rapid in vitro diagnostic solutions for identifying and combating serious infections, particularly those related to antibiotic resistance. Key activities include research and development of the Accelerate Pheno system and Accelerate PhenoTest BC kit, which provide rapid identification and antimicrobial susceptibility testing (ID/AST) results. The segment leverages advanced microbiology techniques and data analytics to improve patient outcomes by enabling faster and more targeted antibiotic therapy. This addresses the critical need for rapid diagnostics in healthcare settings, reducing morbidity, mortality, and healthcare costs associated with bloodstream infections and other severe infections. Future opportunities include expanding the test menu, improving turnaround times, and integrating with hospital information systems.